Abstract
Homoharringtonine (HHT) has been reported to induce hyperglycemia. This report describes a study conducted to characterize the effect of HHT on insulin production and action. Our data indicate that HHT-induced hyperglycemia results from the development of insulin resistance. A review of the literature suggests that patients receiving HHT continuous infusions of 5 mg/m2/d or greater and patients greater than 10 years of age may be at increased risk for the development of HHT-induced hyperglycemia. We recommend that patients with these risk factors, as well as diabetic patients and patients concurrently receiving asparaginase and/or prednisone, have their blood glucoses routinely monitored for hyperglycemia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Alkaloids / adverse effects*
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Blood Glucose / analysis
-
C-Peptide / urine
-
Drug Evaluation
-
Harringtonines / administration & dosage
-
Harringtonines / adverse effects*
-
Homoharringtonine
-
Humans
-
Hyperglycemia / chemically induced*
-
Hyperglycemia / metabolism
-
Infusions, Intravenous
-
Insulin / blood
-
Insulin Resistance
-
Leukemia / complications
-
Leukemia / drug therapy
-
Leukemia / metabolism
-
Risk Factors
-
Time Factors
Substances
-
Alkaloids
-
Antineoplastic Agents, Phytogenic
-
Blood Glucose
-
C-Peptide
-
Harringtonines
-
Insulin
-
Homoharringtonine